As previously mentioned several mechanisms account for β-catenin pathway activation in HCC cells, and these include mutations in β-catenin gene (CTNNB1) or in components of the β-catenin degradation complex (AXIN1), as well as dysregulation in the expression of Wnt/Fizzled signaling elements [11], [26], [27], [47], [55], [61]. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.